Gene Solutions Group proudly announces that our Next-Generation Sequencing laboratory in Singapore has been awarded College of American Pathologists (CAP) accreditation. This honor, granted after a rigorous on-site evaluation, provides recognition of the clinical utility of our circulating tumor DNA (ctDNA) tests, specifically in Multi-Cancer Early Detection (MCED) and Minimal Residual Disease (MRD) monitoring. These are currently the most advanced applications of Next Generation Sequencing (NGS) and Artificial Intelligence (AI) technologies for early cancer screening, therapeutic selection, monitoring treatment efficacy and relapse.
As one of the biotech pioneers in Asia, Gene Solutions now uniquely operates two CAP-accredited laboratories specializing in next-generation sequencing (NGS), within a network of six NGS laboratories.
“The laboratory in Singapore serves as the oncology hub for Gene Solutions, providing MCED and MRD tests to the region, including Singapore, Malaysia, Indonesia, Hong Kong, and Taiwan. Furthermore, we are conducting additional research and clinical trials in Singapore with world-class medical institutions to accelerate genomics breakthroughs that could transform cancer care.” said Dr. Christopher Wong, Director of Gene Solutions Singapore.
By adhering to the stringent standards of the CAP Accreditation Programs, Gene Solutions Genomics joins a distinguished group of over 8,000 CAP-accredited laboratories worldwide. This rigorous process ensures that we not only meet but exceed the highest standards of care, ultimately providing the best possible outcomes for our patients. With over 23,000 laboratory participants, CAP partners with laboratories worldwide to elevate diagnostic standards, ensuring the best outcomes for patients everywhere.
At Gene Solutions, we are honored to stand alongside the world’s leading laboratories, united by our shared vision of advancing diagnostic standards and bringing hope to patients and their families.
About the College of American Pathologists
The College of American Pathologists (CAP) is the world’s largest organization of board-certified pathologists and a leading provider of laboratory accreditation and proficiency testing programs. The CAP advocates for excellence in pathology and laboratory medicine on a global scale. For more information, visit the CAP Newsroom, CAP.org, and yourpathologist.org to see the impactful stories of patients who trust pathologists with their care.
About Gene Solutions Group
Founded in 2017, Gene Solutions has established its 6th Next Generation Sequencing Laboratory in Singapore, providing residents in Asia with convenient access to its screening and diagnostic tests. We are dedicated to improving healthcare outcomes by making cutting-edge genetic tests more accessible to low- and middle-income individuals, supporting both reproductive health and clinical oncology. In the field of clinical oncology, we offer innovative solutions such as personalized minimal residual disease (MRD) detection and multi-cancer early detection (MCED) tests, utilizing advanced ctDNA technology. In partnership with regional clinics, hospitals, and laboratories, Gene Solutions is committed to advancing healthcare through pioneering genetic solutions that drive clinical excellence.
